このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Moleculin Biotech マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Wally Klemp
最高経営責任者
US$1.4m
報酬総額
CEO給与比率 | 39.9% |
CEO在任期間 | 9yrs |
CEOの所有権 | 2.4% |
経営陣の平均在職期間 | 7yrs |
取締役会の平均在任期間 | 7yrs |
経営陣の近況
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Dec 17Moleculin Biotech's annamycin shows encouraging action in animal study
Nov 19Moleculin Biotech EPS beats by $0.04
Nov 13Moleculin further collaborates to advance WP1122 in COVID-19
Oct 29CEO報酬分析
日付 | 総報酬 | 給与 | 会社業績 |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$27m |
Dec 31 2023 | US$1m | US$565k | -US$30m |
Sep 30 2023 | n/a | n/a | -US$26m |
Jun 30 2023 | n/a | n/a | -US$29m |
Mar 31 2023 | n/a | n/a | -US$30m |
Dec 31 2022 | US$2m | US$565k | -US$29m |
Sep 30 2022 | n/a | n/a | -US$25m |
Jun 30 2022 | n/a | n/a | -US$21m |
Mar 31 2022 | n/a | n/a | -US$18m |
Dec 31 2021 | US$2m | US$538k | -US$16m |
Sep 30 2021 | n/a | n/a | -US$16m |
Jun 30 2021 | n/a | n/a | -US$15m |
Mar 31 2021 | n/a | n/a | -US$21m |
Dec 31 2020 | US$2m | US$500k | -US$17m |
Sep 30 2020 | n/a | n/a | -US$19m |
Jun 30 2020 | n/a | n/a | -US$19m |
Mar 31 2020 | n/a | n/a | -US$10m |
Dec 31 2019 | US$2m | US$625k | -US$13m |
Sep 30 2019 | n/a | n/a | -US$12m |
Jun 30 2019 | n/a | n/a | -US$10m |
Mar 31 2019 | n/a | n/a | -US$14m |
Dec 31 2018 | US$1m | US$403k | -US$12m |
Sep 30 2018 | n/a | n/a | -US$12m |
Jun 30 2018 | n/a | n/a | -US$13m |
Mar 31 2018 | n/a | n/a | -US$11m |
Dec 31 2017 | US$1m | US$325k | -US$10m |
報酬と市場: Wallyの 総報酬 ($USD 1.41M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。
報酬と収益: Wallyの報酬は、過去 1 年間の会社の業績と一致しています。
CEO(最高経営責任者
Wally Klemp (64 yo)
9yrs
在職期間
US$1,414,599
報酬
Mr. Walter V. Klemp, also known as Wally, has been the Executive Chairman of Autonomix Medical, Inc. since joining in January 2022. He is President, Chief Executive Officer and Director of Zeno Corporation...
リーダーシップ・チーム
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Founder | 9yrs | US$1.41m | 2.44% $ 204.3k | |
Executive VP & CFO | 7.9yrs | US$840.64k | 0.49% $ 41.2k | |
Chief Scientific Officer | 6.9yrs | US$599.11k | 0.35% $ 29.0k | |
Co-Founder | no data | データなし | データなし | |
Senior Chief Medical Officer | 2.8yrs | データなし | データなし | |
Chief Medical Officer of New Products | 6.7yrs | データなし | データなし | |
European Chief Medical Officer | 2.2yrs | データなし | データなし | |
Consultant | 7yrs | US$69.23k | データなし | |
Independent Advisor | no data | US$118.49k | データなし |
7.0yrs
平均在職期間
69yo
平均年齢
経験豊富な経営陣: MBRXの経営陣は経験豊富で経験豊富です(平均在職期間は6.9年)。
取締役
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Founder | 9yrs | US$1.41m | 2.44% $ 204.3k | |
Co-Founder | no data | データなし | データなし | |
Independent Director | 8.1yrs | US$68.52k | 0% $ 0 | |
Lead Independent Director | 7yrs | US$81.05k | 0% $ 0 | |
Independent Director | 3.8yrs | US$63.52k | 0% $ 0 | |
Member of Annamycin Scientific Advisory Board | less than a year | データなし | データなし | |
Independent Director | 8.1yrs | US$74.90k | 0.042% $ 3.6k | |
Independent Director | 2.3yrs | US$47.15k | 0% $ 0 |
7.0yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: MBRXの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。